CelGro Facilitates Lymphatic Vessel Regeneration Updated
Filed with ASX · · 3 pages · English
Perth, Australia; 02 August 2021: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell”, or the “Company”) advises that the announcement made today has been amended with an updated link to the publication and inclusion of the footnote. There has been no other changes to the announcement, a copy which is attached. Release authorised by Paul Anderson, Managing Director, Orthocell Ltd
Earlier from Orthocell
- CelGro Facilitates Lymphatic Vessel Regeneration
- Orthocell Appoints Exclusive Distributor in Australia
- Positive CelGro Nerve Regeneration Results
- OCC Secures Patents for Sutureless Repair of Soft Tissue
- New Collagen Rope Patent for CelGro Platform Technology
Later from Orthocell
- Appendix 4E and Annual Report to Shareholders
- Ortho-ATI Shoulder Tendon Study Update
- Ortho-ATI Shoulder Tendon Study Update Revised
- OCC Secures Patents for Suture-Less Repair of Soft Tissue
- Positive Data for CelGro Collagen Rope in ACL Reconstruction
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell